References
- National Institute for Clinical Excellence, Technology appraisal 43, Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia, June, 2002.
- Centorrino F, Goren JL, Hennen J, et al. Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits. Am J Psychiatry 2004; 161: 700–706
- Waddington JL, Youssef HA, Kinsella A. Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10 year prospective study. Br J Psychiatry 1998; 173: 325–329
- Edwards S, Kumar V. A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital. Br J Psychiatry 1984; 145: 502–507
- Muijen M, Silverstone T. A comparative hospital survey of psychotropic drug prescribing. Br J Psychiatry 1987; 150: 501–504
- Harrington M, Lelliott P, Paton C, et al. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatr Bull 2002; 26: 414–418
- Taylor DM. Prescribing of clozapine and olanzapine: Dosage, polypharmacy and patient ethnicity. Psychiatr Bull 2004; 28: 241–243
- Taylor D, Mace S, Mir S. A prescription survey of the use of atypical antipsychotics for hospital inpatients in the United Kingdom. Int J Psychiatry Clin Pract 2000; 4: 41–46
- Yorston G, Pinney A. The use of high-dose antipsychotic medication. Psychiatr Bull 1997; 21: 566–569
- Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997; 171: 569–573
- Taylor D. Switching from typical to atypical antipsychotics: Practical guidelines. CNS Drugs 1997; 8(4)285–292
- Lelliott P, Paton C, Harrington M, et al. The influence of patient variables on polypharmacy and combined high dose of antipsychotic drugs prescribed for in-patients. Psychiatr Bull 2002; 26: 411–414
- Kreyenbuhl J, Zito J, Buchanan R, et al. Racial disparity in the pharmacological management of schizophrenia. Schizophr Bull 2003; 29(2)183–193
- Diaz F, De Leon J. Excessive antipsychotic dosing in 2 U.S. state hospitals. J Clin Psychiatry 2002; 63: 998–1003
- Walkup J, McAlpine D, Olfson M, et al. Patients with Schizophrenia at risk for excessive antipsychotic dosing. J Clin Psychiatry 2000; 61: 344–348
- Segal S, Bola J, Watson M. Race, quality of care and antipsychotic prescribing practices in psychiatric emergency services. Psychiatr Services 1996; 47: 282–286
- Jann M, Chang W, Lam Y, et al. Comparison of haloperidol and reduced haloperidol plasma levels in four different ethnic populations. Prog Neuro-Psychopharmacol Biol Psychiatry 1993; 16: 93–202
- Chang W, Jann M, Hwu H, et al. Ethnic comparison of haloperidol and reduced haloperidol plasma levels: Taiwan Chinese versus American Non-Chinese. J Formosan Med Assoc 1991; 90: 572–578
- Zhang-Wong J, Beiser M, Zipursky R, et al. An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res 1998; 81: 333–339
- Lin K, Poland R, Nuccio I, et al. A longitudinal assessment of haloperidol doses and serum concentrations in Asian and Caucasian schizophrenia patients. Am J Psychiatry 1989; 146: 1307–1311